EODData

MEMBERSHIP REGISTER LOG IN

FRA, ISI: Ionis Pharmaceuticals Inc

05 Nov 2025
LAST:

62.98

CHANGE:
 0.08		OPEN:
62.98		HIGH:
62.98		ASK:
0.00		VOLUME:
500
CHG(%):
0.13		PREV:
62.90		LOW:
62.98		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
05 Nov 2562.9862.9862.9862.98500
04 Nov 2562.9062.9062.9062.90500
03 Nov 2563.9463.9463.9463.94500
31 Oct 2563.8663.8663.8663.86500
30 Oct 2561.6261.6261.6261.62500
29 Oct 2562.5662.5662.5662.56500
28 Oct 2562.3462.6662.3462.66500
27 Oct 2560.8660.8660.8660.865
24 Oct 2561.6461.6461.6461.645
23 Oct 2561.1861.1861.1861.185

COMPANY PROFILE

Name:Ionis Pharmaceuticals Inc
About:Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); Donidalorsen for patients with hereditary angioedema; and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 that has completed Phase 2 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.
Sector:Healthcare
Industry:Biotechnology
Address:2855 Gazelle Court, Carlsbad, CA, United States, 92010
Website:https://www.ionis.com
ISIN:US4622221004
LEI:549300SI4ZGLG0BLUZ92

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-20.69 
Forward P/E:-36.33 
PEG Ratio:0.08 
Price to Sales:10.77 
Price to Book:16.67 
Profit Margin:-0.27 
Operating Margin:-1.02 
Return on Assets:-0.06 
Return on Equity:-0.40 
Revenue:839.22M 
Shares:159.39M 
Market Cap:10.038B 

TECHNICAL INDICATORS

MA5:63.060.1%
MA10:62.420.9%
MA20:61.712.1%
MA50:54.0416.5%
MA100:44.5541.4%
MA200:36.8870.8%
STO9:68.83
STO14:68.83
RSI14:59.14
WPR14:-31.17
MTM14:1.38
ROC14:0.02 
ATR:0.80 
Week High:63.941.5%
Week Low:61.622.2%
Month High:63.941.5%
Month Low:59.3270.8%
Year High:63.941.5%
Year Low:22.92174.8%